Modalis Therapeutics Corporation (TYO:4883)
Japan · Delayed Price · Currency is JPY 33.00
0.00 (0.00%)
Aug 27, 2026, 3:30 PM JST
Modalis Therapeutics Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3,015 | 2,812 | 3,575 | 1,883 | 2,933 | 4,936 |
Cash & Short-Term Investments | 3,015 | 2,812 | 3,575 | 1,883 | 2,933 | 4,936 |
Cash Growth | -7.54% | -21.34% | 89.86% | -35.80% | -40.58% | -8.95% |
Inventory | - | - | - | 6 | 40 | - |
Other Current Assets | 68 | 80 | 42 | 67 | 88 | 131 |
Total Current Assets | 3,083 | 2,892 | 3,617 | 1,956 | 3,061 | 5,067 |
Property, Plant & Equipment | - | - | - | - | - | 223 |
Long-Term Investments | 52 | 71 | 74 | 69 | 68 | 73 |
Other Intangible Assets | - | - | - | - | - | 705 |
Other Long-Term Assets | 1 | 1 | - | - | - | 1 |
Total Assets | 3,136 | 2,964 | 3,691 | 2,025 | 3,129 | 6,069 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1 | 1 | 1 | - | - | 1 |
Accrued Expenses | 49 | 25 | 20 | 91 | 17 | 25 |
Current Income Taxes Payable | 337 | 107 | 95 | 105 | 123 | 126 |
Other Current Liabilities | 2 | 1 | 1 | 2 | 1 | 28 |
Total Current Liabilities | 659 | 134 | 117 | 198 | 141 | 180 |
Long-Term Debt | - | - | - | 412 | - | - |
Long-Term Deferred Tax Liabilities | - | - | - | - | - | 5 |
Other Long-Term Liabilities | 6 | 38 | 28 | 36 | 49 | 335 |
Total Liabilities | 665 | 172 | 145 | 646 | 190 | 520 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 885 | 1,728 | 1,758 | 1,217 | 2,094 | 2,744 |
Additional Paid-In Capital | 2,207 | 3,049 | 3,080 | 2,539 | 3,416 | 4,066 |
Retained Earnings | -697 | -2,037 | -1,325 | -2,410 | -2,605 | -1,266 |
Comprehensive Income & Other | 76 | 52 | 33 | 33 | 34 | 5 |
Shareholders' Equity | 2,471 | 2,792 | 3,546 | 1,379 | 2,939 | 5,549 |
Total Liabilities & Equity | 3,136 | 2,964 | 3,691 | 2,025 | 3,129 | 6,069 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 270 | - | - | 412 | - | - |
Net Cash (Debt) | 2,745 | 2,812 | 3,575 | 1,471 | 2,933 | 4,936 |
Net Cash Growth | -15.82% | -21.34% | 143.03% | -49.85% | -40.58% | -8.95% |
Net Cash Per Share | 31.76 | 36.39 | 77.50 | 47.50 | 100.77 | 171.67 |
Filing Date Shares Outstanding | 97.33 | 89.55 | 73.55 | 33.81 | 30.09 | 29.04 |
Total Common Shares Outstanding | 97.33 | 86.67 | 69.4 | 33.36 | 29.36 | 28.97 |
Working Capital | 2,424 | 2,758 | 3,500 | 1,758 | 2,920 | 4,887 |
Book Value Per Share | 25.39 | 32.21 | 51.09 | 41.34 | 100.09 | 191.56 |
Tangible Book Value | 2,471 | 2,792 | 3,546 | 1,379 | 2,939 | 4,844 |
Tangible Book Value Per Share | 25.39 | 32.21 | 51.09 | 41.34 | 100.09 | 167.22 |